Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Taps New Contract Business As Route To Novel Drugs

Executive Summary

Celltrion has opted to use its biologics CDMO business as part of its first open innovation strategy to access and develop novel drugs by sharing development costs or licensing in product candidates, a move seen as unique among biosimilar companies.

You may also be interested in...



Samsung Looks Beyond Biosimilars Via Takeda Tie-Up

Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.

Interview: Celltrion's Journey To The Top

In just 15 years since its establishment, Celltrion has transformed from a modest contract manufacturer in South Korea into a global leader in antibody biosimilars. In this instalment of Scrip’s Leadership Series, CEO Woo Sung Kee talks about what it has taken for the company and its top management to achieve such rapid growth, its ambitions to enter the global top 10 biotech firms, and his own work philosophy.

Lunsumio Provides First Test For Korea's Breakthrough Therapy Program

South Korea's breakthrough therapy system, Global Innovative Products Fast Track, kicks off with Roche’s follicular lymphoma drug becoming the first to test the new system. Meanwhile, a state-run group is linking with pharma firms to rapidly bring in global new drugs.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel